12:17 PM EST - Lobe Sciences Ltd : Today announced it has developed its initial Phase 1 study plan intended to demonstrate the safety and appropriate dosing range for its proprietary new chemical entity; L-130. It is also announcing the acquisition of a second new chemical entity, L-131, which is expected to enter preclinical toxicity trials later this year or early in 2023. Lobe remains committed to discovering and developing psychedelic derived medicines. Lobe Sciences Ltd
shares C.LOBE are trading unchanged at $0.05.
